Description
Alanine Transaminase (ALT), also known as alanine aminotransferase (ALAT) or serum glutamic pyruvic transaminase (sGPT), is a homodimeric cytoplasmic pyridoxal phosphate-
dependent enzyme involved in cellular nitrogen metabolism, amino acid metabolism, and liver gluconeogenesis. ALT mediates conversion of major intermediate metabolites, catalyzing reversible transamination between alanine and α-
ketoglutarate to form pyruvate and glutamate. ALT is widely distributed in many tissues but is found in greatest abundance in the liver, and to a much lesser extent in the kidneys, heart, and brain. The major role of ALT in the liver is the conversion of alanine to glucose which is then exported to the body to be utilized in a multitude of processes. ALT has also been found to play an important role in neuronal function by supplying an important source of neuronal glutamate through the analine-
aminotransferase reaction. Serum ALT levels are generally low, but may spike during disease states or in the event of tissue injury. As such, ALT levels are routinely used as indicators of medical issues, particularly liver diseases. Increased levels can be seen in patients with diabetes, cirrhosis, fatty liver disease, and hepatitis. Beyond liver disease, increased ALT levels have been noted in cases of carcinoma, mononucleosis, muscular dystrophy, and cardiovascular disease. Cayman’s Alanine Transaminase Colorimetric Assay Kit provides a convenient method of detecting ALT activity in serum, plasma, tissue samples, and cell lysates. Measurement of the ALT activity is carried out by monitoring the rate of NADH oxidation in a coupled reaction system employing lactate dehydrogenase (LDH). The oxidation of NADH to NAD
+ is accompanied by a decrease in absorbance at 340 nm. Under circumstances in which the ALT activity is rate limiting, the rate decrease is directly proportional to the ALT activity in the sample.
References
[1] PADILLA M S, MRKSICH K, WANG Y, et al. Branched endosomal disruptor (BEND) lipids mediate delivery of mRNA and CRISPR-Cas9 ribonucleoprotein complex for hepatic gene editing and T cell engineering[J]. Nature Communications, 2025, 2 1. DOI:
10.1038/s41467-024-55137-6[2] XUEXIANG HAN. In situ combinatorial synthesis of degradable branched lipidoids for systemic delivery of mRNA therapeutics and gene editors.[J]. Nature Communications, 2024, 15 1: 1762. DOI:
10.1038/s41467-024-45537-z[3] XUEXIANG HAN. Fast and facile synthesis of amidine-incorporated degradable lipids for versatile mRNA delivery in vivo[J]. Nature chemistry, 2024, 16 10: 1687-1697. DOI:
10.1038/s41557-024-01557-2[4] RACHEL S. RILEY. Ionizable lipid nanoparticles for in utero mRNA delivery[J]. Science Advances, 2021, 7 3. DOI:
10.1126/sciadv.aba1028[5] MINZHI YU Troy H Kristen Hong Dorsey, ANNA SCHWENDEMAN* Enhancement of Anti-inflammatory Effects of Synthetic High-Density Lipoproteins by Incorporation of Anionic Lipids[J]. Molecular Pharmaceutics, 2023, 20 11: 5454-5462. DOI:
10.1021/acs.molpharmaceut.3c00175[6] XUEXIANG HAN. Ligand-tethered lipid nanoparticles for targeted RNA delivery to treat liver fibrosis.[J]. Nature Communications, 2023, 14 1: 75. DOI:
10.1038/s41467-022-35637-z[7] POONAMJOT DEOL. Omega-6 and omega-3 oxylipins are implicated in soybean oil-induced obesity in mice.[J]. Scientific Reports, 2017: 12488. DOI:
10.1038/s41598-017-12624-9[8] FENGJUN LIU. Parallel comparative studies on toxicity of quantum dots synthesized and surface engineered with different methods in vitro and in vivo.[J]. International Journal of Nanomedicine, 2017: 5135-5148. DOI:
10.2147/ijn.s137637[9] BENJAMIN L FARAH. β-Adrenergic agonist and antagonist regulation of autophagy in HepG2 cells, primary mouse hepatocytes, and mouse liver.[J]. PLoS ONE, 2014: e98155. DOI:
10.1371/journal.pone.0098155
